Merck wins second Vioxx trial

Share this article:
The jury in the Atlantic City, N.J. Vioxx trial has found Merck not liable.
Merck lawyers persuaded jurors that the heart attack suffered by Idaho postal worker Frederick Humeston was unrelated to his two-month use of Vioxx, citing a host of other cardiovascular risk factors suffered by the plaintiff.
The verdict, following the $253 million decision against Merck in plaintiff-friendly Angleton, Texas last August, should provide a big boost for morale at Merck and could have implications for future Vioxx litigation, as a string of wins for Merck or a mixed record could deter trial lawyers from pursuing lengthy and costly lawsuits against the company. The firm still faces more than 6,000 suits alleging injuries due to Vioxx, which Merck pulled little more than a year ago after studies showed the drug increased cardiovascular risks in patients with preexisting heart conditions.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.